Exicure, Inc. is a biotechnology company pioneering the development of nucleic acid-based therapeutics aimed at treating rare and severe genetic diseases and cancer. Utilizing their proprietary Spherical Nucleic Acid (SNA) technology, Exicure enables the delivery of genetically targeted therapies to a wide range of tissues and cells. This technology has demonstrated potential applications in preclinical studies for the central nervous system (CNS), eye, lung, and gastrointestinal (GI) tract.

Exicure operates in the biopharmaceutical market, primarily serving patients with unmet medical needs due to rare genetic disorders and various forms of cancer. The company's business model revolves around the research, development, and eventual commercialization of its therapeutic candidates. Revenue generation is expected through partnerships, licensing agreements, and future sales of approved therapies.

Exicure's SNA technology overcomes significant challenges in the delivery of nucleic acid therapeutics, offering high transfection efficiency into numerous cell and tissue types without the need for carriers or transfection agents. This positions the company at the forefront of innovative treatment solutions in the biotech industry.

Keywords: SNA technology, nucleic acid therapeutics, genetic diseases, cancer treatment, biotechnology, CNS, eye, lung, GI tract, transfection efficiency, biopharmaceutical.